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Abstract
Oral and long-acting injectable second-generation antipsychotics are known to be associated with a high risk of metabolic adverse effects. Together with other drug treatments, poor lifestyle choices and genetic liability, they contribute to development of metabolic syndrome (MetS), that occurs in nearly one-third of patients with schizophrenia. 
The primary objective of this multicenter prospective observational study was to explore the prevalence of MetS in a sample of 60 real-world patients treated with paliperidone palmitate (PP) over a period of 12 months. The secondary objectives were to assess other tolerability aspects and the efficacy of PP on schizophrenic symptoms. 
The proportion of patients with MetS at baseline (33%) did not significantly change neither at 6 (39.0%) nor at 12 months (29.5%) of PP treatment. The same applies to each individual component of MetS. We found a slight but statistically significant increase of BMI (26.3±6.0 vs 27.1±4.6: p=.031) and of waist circumference (98.2±17.9 vs 100.3±15.9: p=.021) from baseline to endpoint. Weight gain was detected in approximately 15% of patients. 
At least one mild or moderate adverse event was found in 71.3%, 88.0% and 52.1% of patients respectively at baseline, 6 and 12 months. A significant improvement in schizophrenic symptoms emerged by means of PANSS total and subscale scores. 
Together with previous literature findings, our results seem to indicate that PP could be a valid therapeutic option for patients with a severe disorder and with a high metabolic risk profile. 
Introduction
Schizophrenia is a chronic, disabling and progressive disease with a lifetime prevalence of 0.8% to 1% of the general population 1,2. The treatment of schizophrenia requires long-term antipsychotics, to both manage disease symptoms and delay relapses 3. Second generation antipsychotics (SGAs) are generally preferred over typical antipsychotics for schizophrenia treatment as they are associated with fewer extrapyramidal symptoms (EPSs), lower risk of tardive dyskinesia, and possibly greater improvement in negative symptoms 4. However, several SGAs are known to be associated with a high risk of metabolic adverse effects such as weight gain, hyperlipidemia and hyperglycemia 4,5. Glucose dysregulation 6, glucose intolerance 7 and increased cholesterol levels 8 can frequently occur in patients taking SGAs. Thus, together with other drug treatments, poor lifestyle choices and genetic liability, SGAs contribute to development of metabolic syndrome (MetS), that occurs in nearly one-third of patients with schizophrenia 9,10. MetS increases the risk for cardiovascular diseases, insulin resistance and diabetes mellitus, and can lead to increased morbidity and mortality, in addition to impairing patient adherence to medication 11. 
Long-acting injectable (LAI) antipsychotics confer better protection against psychotic relapse than their oral equivalents 12,13, at least in part, by improving adherence 14,15.  Like their oral progenitors, second-generation LAIs tend to have a lower incidence of EPSs than first-generation LAIs, but they have been associated with further adverse events, including metabolic disturbances and cardiovascular events.
Paliperidone palmitate (PP), a second-generation LAI antipsychotic, has been shown to be effective for the treatment of schizophrenia 16. Particularly, a recent study found that PP is noninferior to risperidone LAI in improving both positive and negative symptoms of schizophrenia, also in markedly-to-severely ill subjects 17.
Nevertheless, there is still little data on the relationship between PP and adverse metabolic effects. Although some studies have focused on safety and adverse metabolic events during PP treatment 17-19, today no studies have assessed the prevalence of MetS in subjects receiving PP treatment in normal clinical practice.





This is a multicenter prospective observational study conducted in a sample of in- and outpatients with schizophrenia treated with PP. Two sites in Piedmont region of Italy took part in the study: 
1)	the Psychiatric Clinic of San Luigi Gonzaga Hospital of Orbassano (Torino), a tertiary referral center located within the University General Hospital;
2)	the Mental Health Department  of Alba and Bra (Cuneo).
Study participants were recruited from patients living in the community and referred by general practitioners or psychiatrists, although a few are self-referred.
All recruited patients entered the study at the start of the treatment with PP (baseline) and were followed-up over a period of 12 months. Since this was an observational study, no attempt was made to influence decisions regarding the study treatment and patients received care as usual.  

Sample
Eligible patients were male and female in- and outpatients aged ≥ 18 years. The recruitment lasted 1 year (May 2013 – May 2014).
To be enrolled, patients had to fulfill the following criteria: (a) main diagnosis of schizophrenia according to Diagnostic and Statistical Manual of Mental Disorders – 5th edition (DSM-5); (b) starting treatment with PP; (c) consent to participate in the study.
The exclusion criteria for the investigation were: (a) main diagnosis other than schizophrenia; (b) concomitant severe, unstable, active neurological or physical diseases; (c) history of non- response or intolerance to paliperidone.

Treatment
Paliperidone palmitate, after an initial regimen of two intramuscular injections of 150 milligram equivalents (mg eq.) and of 100 mg eq. one week later, was administered once monthly using flexible maintenance dosage within the range of 50 to 150 eq. 
From the start of the study, patients were tapered off their previous antipsychotics within a (maximum) four week period, based on clinical judgment. Patients who had never taken oral or injectable forms of PP or risperidone were given oral risperidone or paliperidone (two daily oral doses of either 1 mg risperidone or 3 mg paliperidone) prior to starting PP.
Other psychotropic medication for reason other than the disease itself (eg, anxiety, mood symptoms and sleep induction) were allowed. Drugs for medical conditions were allowed as well.

Assessments and procedures 
At the study entry point, socio-demographic and clinical characteristics were collected about each subject. Lifestyles were also investigated: information about exposure to cigarette smoke, the amount of alcohol consumed and physical exercise taken, were obtained by directly interviewing the patients. Also, comorbidity, family history for diabetes or cardiovascular diseases, and current treatments for hypertension, diabetes, or dyslipidemia were assessed by looking at medical reports, and by direct interviews.
The MetS was assessed through a protocol already used in previous studies 20. Weight, height, waist circumference, and blood pressure were measured. The patients had been fasting and were undressed for the weight measurement. Height was measured barefoot. A weight gain of at least 7% from baseline was considered significant. The waist circumference, measuring central adiposity, was taken at midway between the inferior margin of the ribs and the superior border of the iliac crest, at minimal respiration. Two blood pressure measurements were taken using a mercury sphygmomanometer: the first with the subject in a lying position, the second with the subject in a seated position for at least two minutes after the first measurement. The mean blood pressure of the two measurements was used. An attending hospital physician performed all procedures. A routine blood test was performed. The blood test included glucose, total cholesterol, triglycerides, LDL and HDL-C levels. 
The MetS was diagnosed in the patients according to the National Cholesterol Education Program (NCEP) Adult Treatment Panel (ATP) III-modified criteria 21:
• Abdominal obesity: waist circumference ≥ 102 cm in men and ≥88 cm in women
• Hypertriglyceridemia: ≥150 mg/dl or on lipid-lowering medication
• Low HDL-C: b40 mg/dl in men and b50 mg/dl in women
• High blood pressure: systolic pressure ≥130 mm Hg and/or diastolic pressure ≥85 mm Hg or on antihypertensive medication;
• High fasting glucose: ≥100 mg/dl or on glucose-lowering medication
Other tolerability aspects were assessed as follows:
a)	Dosage Record and Treatment Emergent Symptoms Scale (DOTES);
b)	Abnormal Involuntary Movement Scale (AIMS);
Efficacy of PP was assessed through the following scales:
a)	Positive and Negative Syndrome Scale (PANSS);
b)	Hamilton Depression Rating Scale (HAM-D);
Patients were assessed at baseline (T0), after 6 months (T1) and after 12 months (T2) of treatment with PP. 

Statistical analysis
Subjects characteristics were summarized as means and SD for continuous variables and as frequencies and percentages for categorical variables.
We calculated the prevalence of MetS and its criteria at baseline and at subsequent assessment points in the whole sample. We assessed the change in metabolic parameters for waist circumference, blood pressure, triglycerides, HDL cholesterol, and glucose over time by using paired-samples t-test. Paired-samples t-tests were also used to evaluate changes in mean scores of assessment scales (DOTES, AIMS, PANSS and HAM-D) at each assessment point. Pearson correlation analyses were performed to assess associations between BMI scores at the start of study and metabolic parameters such as glycemia, triglycerides, total and HDL cholesterol at each assessment point.
Finally, we assessed the change in the development of abdominal obesity, hypertension, hypertriglyceridemia, low HDL-c, hyperglycemia, and MetS at baseline and at subsequent assessment points using McNemar's chi-square test for within-subjects variables. 

Results
The total number of 320 patients with schizophrenia were treated at the two study sites during the enrollment period: 196 males (61.2%) and 124 females (38.8%) with a mean age of 43,6 (±15.6) years and a mean duration of the disease of 19.1 (± 15.2) years. Of those, 89 who were eligible for treatment with PP were screened for this study. Thirty-nine were excluded for the following reasons: unclear diagnosis (schizoaffective disorder or bipolar disorder with psychotic features, n=11), unstable medical conditions (n=3), history of non-response or intolerance to risperidone or paliperidone (n=10), refused consent (n=15). Sixty participants were recruited. Their socio-demographic and clinical characteristics at baseline are presented in table 1. The mean age of the recruited patients was 42.3 (± 14.4) years. There was a prevalence of male gender (n=42, 70%) and the majority of the patients had a long-term disease, with a mean duration of 19.9 (± 14.3) years. The percentage of patients in current treatment with antipsychotics (oral or depot) was 63.3%. All included subjects had a history of past treatment with one or more antipsychotics and other psychiatric drugs. There was a high rate of medical conditions (41.7%), especially endocrine or metabolic diseases (16.7%). The recruited subjects (n=60) were comparable to the population of patients with schizophrenia treated at the two study sites (n=320) in terms of demographic and clinical features (no statistically significant differences).

Table 1. Baseline demographic and clinical characteristics.

There were 44 patients who completed the study (n=44) (73.3%). One patient was lost to follow-up between T0 and T1. Fifteen of the 59 patients with T1 assessment discontinued treatment before T2 (see also fig. 1). Of them, 5 patients were lost to follow-up, 3 subjects discontinued treatment due to inefficacy and 7 due to intolerance (11.6%). Extrapyramidal symptoms (n=4), depressed mood (n=4), psychomotor retardation (n=3) and weight gain (n=3), were the mostly reported adverse events (AEs) among those who stopped medication. 
The mean dose of PP was 104.41 (± 31.50) and 100.57 (± 33.88) mg eq respectively at T1 and T2. 

Primary outcomes
The metabolic parameters (continuous variables) assessed at each evaluation point are shown in table 2: there was a slight increase in the mean scores of BMI between T0 and T1 (26.3 vs 27.4 p=.04) and between T0 and T2 (26.3 and 27.1: p=.031). Similarly, the mean scores of waist circumference significantly increase between T0 and T1 (98.2 vs 100.3 cm: p=.021) and between T0 and T2 (98.2 vs 101.1 cm: p=.021). No statistically significant differences were found in blood pressure, glycemia, tryglicerides, total and HDL cholesterol mean scores at each assessment point. 

Table 2. Metabolic parameters at the three evaluation points.

In order to check whether BMI at study entry (T0) could have had an effect on metabolic parameters across the study period, we performed Person bivariate correlation analyses, which revealed significant associations. There were positive correlations between BMI and triglyceredimia at T1 (r=.266, p=.041) and at T2 (r=.298, p=.050) and negative correlations between BMI and HDL levels at T1 (r=-488, p<.001) and at T2 (r=-323, p=.033).
Table 3 shows the comparisons between MetS criteria (categorical variables) at the three evaluation points.  The MetS rates at T0, T1 and T2 were respectively 33.3%, 39.0%, and 29.5% (without statistical differences). 

Table 3. Prevalence of metabolic syndrome (MetS) and its individual components at the three evaluation points.

A subgroup of 4 patients with MetS at baseline did not fulfilled MetS criteria at T1, as well as a subgroup of 5 patients with MetS at T1 did not fulfilled MetS criteria at T2. Conversely, 7 patients without MetS at the entry of the study and 2 patients without MetS at T1 fulfilled Mets criteria respectively at T1 and T2 (see also fig. 1). Among the study completers without MetS at baseline (n=30), only two patients (6.6%) fulfilled MetS criteria at the end of the study period (12 months). Conversely, among study completers with MetS at baseline (n=14), 4 patients (28.5%) did not fulfilled MetS criteria at the end of the study period.

Figure 1. Patients with metabolic syndrome (MetS) at each assessment point.

Secondary outcomes 
With regards to AEs assessed by DOTES, the results are reported in table 4. At least one AE was found in 71.3%, 88.0% and 52.1% of patients respectively at TO, T1 and T2. The most common AEs at T0 were: affective flattening (23.3%), tremor (20.0%), reduced motor activity (18.3%), insomnia (16.6%), weight gain (15%), and constipation (15.0%). The most common AEs at T1 were: reduced motor activity (33.9%), tremor (18.6%), constipation (18.6%), weight gain (16.9%), and muscle rigidity (16.9%). The most common AEs at T2 were: tremor (27.3%), increased motor activity (22.7%), weight gain (15.9%).
Hyperprolactinemia was detected in 4 (6.6%) patients at baseline, 6 (10.1%) patients at T1 and in 6 (13.6%) patients at T2. Hyperprolactinemia was symptomatic in 2 women that showed amenorrhea. 
There were statistically significant differences in the DOTES mean score between baseline and T1(13.2 vs 18.7: t=-2.495; d.f.=59; p=.015), and between T1 and T2 (18.7 vs 11.0: t=3.623; d.f.=59; p=<.001). 

Table 4. Side effects assessed by DOTES at T0, T1 and T2.

EPSs were found in 37.2% and 36.6% of patients respectively at T1 and T2. The AIMS mean scores at each evaluation point were respectively 4.1(± 5.3), 4.3(± 4.7) and  4.8(± 5.7) without statistically significant differences. 
PANSS total scores (mean ± S.D.) were respectively 102.7 (± 16.1), 78.8 (± 18.9) and 78.6 (± 17.2) at the three assessment points, with statistically significant differences between T0 and T1 (p=.001) and between T0 and T2 (p=.001). The proportion of patients with clinically significant improvement in PANSS at the endpoint was respectively 40% (≥20% improvement), 28.3% (≥30% improvement), and 5.0% (≥50% improvement). 
With regards to PANSS subscales, PANSS Positive Subscale mean scores decreased significantly from T0 to  T1 (25.96 ± 7.5 vs 17.44 ± 4.9: t=9.75, p<.001) and from TO to T2 (26.05 ± 7.4 vs 16.45 ± 4.037: t=8.18, p<.001).  
Similarly, a reduction of PANNS Negative Subscale mean scores was detected both from T0 to T1 (23.09 ± 6.4 vs 21.02 ± 6.7: t=3.72, p<.001) and from TO to T2 (23.14 ± 6.6 vs 20.73 ± 7.0: t=3.15, p<.001), and PANNS General mean scores significantly decreased from T0 to T1 (55.05 ± 10.4 vs 41.16 ± 8.9: t=9.012, p<.001) and from T1 to T2 (54.95 ± 11.3 vs 41.11 ± 9.7: t=6.584, p<.001)
There was a statistically significant reduction of the HAM-D mean scores from baseline to T1  (15.0 ± 7.7 vs 9.1 ± 4.4: p=.001) and from baseline to T2 (15.0 ± 7.7 vs 8.4 ± 4.0: p=.001). No significant differences emerged in HAM-D mean scores at T1 and T2.

Discussion
This was a 12-month prospective observational study of 60 patients with schizophrenia being treated with PP. Inclusion/exclusion criteria were designed to recruit a diverse study group. Patients with a current substance use or abuse and/or other psychiatric comorbidities were eligible for enrolment and there were no exclusions based on medical illnesses (except acute conditions). In our sample there was a prevalence of males (70%), but it is known that the sex ratio differs across patient groups with higher incidence rates of males in samples who are characterized by the long duration of the disorder (DSM-5). Furthermore, there were no statistically significant differences in sex ratio between the total number of 320 patients with schizophrenia treated at the two study sites during the enrollment period and the recruited patients (n=60). The high prevalence of intellectual disability (11.7%) observed in our sample could be due to the following reasons: inbreeding – many patients from isolated rural areas where the marriage between blood relatives (leading to a greater genetic risk) was not uncommon; limited access to specific programs for the early detection and treatment of such disorders because of a certain geographical isolation, low socioeconomic status and the more frequent use of LAI antipsychotics in such patients because of their poor compliance to oral treatments. 
It must be emphasized that most patients were severely ill. PANNS baseline mean scores were definitely higher than those of patients recruited in other studies on PP 17, 19, 22.   
PP was continued for 12 months after the start of the study in more than two-thirds of the subjects and discontinuations because of AEs were uncommon (n=7, 11.6%). Similarly, the discontinuation rate due to intolerance in a recent 1-year observational study on patients treated with PP was 14.7% 23 and in a recent 15-month study on real-world outcomes of PP in patients with schizophrenia, treatment-emergent AEs leading to study drug discontinuation occurred in 11.9% of patients 24.
The primary objective of the present study was to explore putative metabolic alterations with particular regard to MetS components. It is known that metabolic effects are of concern in patients receiving SGAs 25-28. A retrospective chart review of schizophrenic patients strengthened the link between SGAs and MetS: following 3 years of treatment exposure, the rate of MetS increased fivefold from baseline in those receiving SGAs. It also revealed that SGAs such as clozapine and olanzapine showed a greater risk for the development of MetS, with 58.3% and 47.1% being diagnosed with the syndrome at follow-up 9. The association between SGAs and MetS was found also in patients with psychiatric disorders other than schizophrenia. A recent study found that bipolar patients developed MetS over a 2 year follow-up period were taking antipsychotics at baseline, most of which were atypical antipsychotics, confirming the increased risk associated with this class of medication 20. 
In the present study the rate of MetS at baseline was 33.3%. This result is consistent with findings of recent literature on this topic. A systematic review and meta-analysis stated that the overall rate of MetS in adults with schizophrenia and related disorders was 32.5% 10. Moreover, in our sample the proportion of patients with MetS at baseline (33%) did not significantly change neither at 6 (39.0%) nor at 12 months (29.5%) of PP treatment. The same applies to each individual component of MetS (abdominal obesity, high blood pressure, high fasting glucose, hypertriglyceridemia, low HDL-c). 
We found a slight but statistically significant increase of BMI and of waist circumference (mean scores) both at T1 and T2. This data is consistent with the proportion of weight gain assessed by DOTES at T1 (16.9%) and at T2 (15.9%). Similarly, a recent unblinded 6-month study on patients with schizophrenia treated with paliperidone flexible-dose reported a ≥7% increase in weight in 15.4% of patients 29. 
In a recent study on metabolic parameters in patients treated with PP, occurrences of metabolic adverse events trended with greater BMI status 18. Similarly, in our study correlations between higher scores of BMI at baseline and higher levels of triglycerides after 6 and 12 months of PP treatment emerged. Also, greater BMI status at baseline was associated with lower levels of HDL cholesterol at T1 and T2.  Nevertheless, no metabolic AEs leading to discontinuation occurred.
The secondary objectives were to assess other tolerability aspects and the efficacy of PP on schizophrenic symptoms.
We found high rates of AEs (88%) not leading to drug discontinuation at T1. Other studies examining PP tolerability found lower treatment-related AEs rates. For example, a pragmatic interventional study in a large sample of patients of schizophrenia (the PALMFlexS study) found at least one AE in 59.7% of patients 29. The high rates of AEs in our study could be firstly explained by the characteristics of the sample, which included many patients with long-term disease, concurrent medical conditions, many previous antipsychotic treatments and other concomitant drugs throughout the study period. As a matter of fact, in the study of Alphs and colleagues 24 on a group in which many of the patients had a severe and long-term schizophrenia, PP related AEs were reported in 85.5%. Moreover, in our study the total number of AEs increased from baseline to T1, with a statistically significant difference of DOTES mean scores. This could be related to the study drug. At T2, AEs rate (52.1%) was lower than at T1 and consistent with other findings 29. Further, there was a statistically significant decrease of DOTES mean scores between T1 and T2. This could be explained by the fact that 15 of 59 patients assessed at T1 didn't complete the study, including seven due to AEs. Despite this, most AEs both at T1 (93.1%) and at T2 (94.5%) were rated by clinicians as mild or moderate in intensity.
With regard to EPSs, about one third of recruited patients showed EPSs both at T1 and T2 and in 3 patients EPSs led to the discontinuation of PP. Furthermore, the AIMS mean scores increased at each evaluation point, although no statistically significant differences were found. Paliperidone is well known to produce extrapyramidal side effects 30. Therefore, the lack of statistical significance between baseline and endpoint AIMS scores in our study must be considered in view of the low number of subjects. On the other hand, other studies in patients with schizophrenia treated with PP found lower EPSs rates 17. 
With respect to efficacy of PP, only three patients (5% of the recruited sample) stopped medication due to lack of efficacy. This data is in line with the proportion of patients (2.5%) who discontinued PP early because of lack of efficacy in the PALMFlexS study 29. A similar discontinuation rate (7.5%) due to lack of efficacy in the PP group was also shown by the Fu and colleagues study 17. 
Furthermore, a significant decrease in schizophrenic symptoms was detected by means of PANSS total and subscales scores. Since the majority of recruited patients were severely ill and with a long-term disease, the substantial mean reduction (around 25 points) of PANSS total score at 6-month follow-up must be highlighted. This result is in line with PANSS mean change found by Fu and colleagues 17 in a sample of schizophrenic patients. Furthermore, in our sample both positive and negative subscales scores improved and depressive symptoms significantly decreased. This data is in line with previous findings. First, in patients with acute symptoms, paliperidone ER has been shown to be significantly more effective than placebo for negative symptoms 31-33. Second, a previous analysis suggested that paliperidone ER improves negative symptoms of schizophrenia beyond the indirect effects on positive symptoms and anxiety/depression 34. 
Some key methodological limitations have to be considered when this data is interpreted. First, the loss of 6 individuals at the follow up (10% of the total sample) could be a source of bias. Second, the heterogeneity of recruited patients in terms of clinical characteristics (e.g. medical conditions, drug treatments other than study medication) with potential confounding factors. The limitations of this study also includes the small sample size and the absence of a control group. On the other hand, a point of strength that should be taken into account: subjects enrolled for this study were representative of ‘real-world’ in and out-patients with schizophrenia. 
In conclusion, to our knowledge this study is the first in which MetS was investigated with all of its parameters in subjects treated with PP. Although SGAs have consistently been shown to be related to metabolic alterations in patients with schizophrenia, this study showed that MetS rates did not increase after 12 months of treatment with PP.  Furthermore, our results suggest that PP is generally effective in patients with a severe and long-lasting illness and with high rates of comorbid medical illnesses including cardiovascular and endocrine/metabolic conditions. Together with previous literature findings, our results seem to indicate that PP could be a valid therapeutic option for patients with a severe disorder and with a high metabolic risk profile. 
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